{"id":"temozolomide-and-lomustine","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Myelosuppression (thrombocytopenia, leukopenia)"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Hepatotoxicity"},{"rate":"1-5","effect":"Secondary malignancy"}]},"_chembl":{"chemblId":"CHEMBL810","moleculeType":"Small molecule","molecularWeight":"194.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are nitrosoureas/alkylating agents that methylate DNA at the O6-guanine position, leading to DNA strand breaks and apoptosis. Temozolomide is a prodrug converted to its active form MTIC, while lomustine acts directly. The combination targets rapidly dividing cells and is particularly suited for CNS penetration in glioblastoma and other brain malignancies.","oneSentence":"Temozolomide and lomustine are alkylating agents that cross the blood-brain barrier and cause DNA damage to kill cancer cells, particularly effective in brain tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:56.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma multiforme"},{"name":"Recurrent or progressive high-grade glioma"}]},"trialDetails":[{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT05095376","phase":"PHASE3","title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-28","conditions":"Glioblastoma, Gliosarcoma","enrollment":265},{"nctId":"NCT05331521","phase":"PHASE3","title":"A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2021-04-07","conditions":"Oligodendroglioma","enrollment":406},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT04049669","phase":"PHASE2","title":"Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theodore S. Johnson","startDate":"2019-10-02","conditions":"Glioblastoma, Medulloblastoma, Ependymoma","enrollment":130},{"nctId":"NCT05902169","phase":"PHASE3","title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"CarThera","startDate":"2024-01-29","conditions":"Glioblastoma, Recurrent Glioblastoma, GBM","enrollment":560},{"nctId":"NCT03970447","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2019-07-30","conditions":"Glioblastoma","enrollment":1280},{"nctId":"NCT03149575","phase":"PHASE3","title":"VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","status":"TERMINATED","sponsor":"DelMar Pharmaceuticals, Inc.","startDate":"2017-10-27","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":2},{"nctId":"NCT07120984","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma","status":"NOT_YET_RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2026-01-30","conditions":"Glioma","enrollment":52},{"nctId":"NCT04135807","phase":"EARLY_PHASE1","title":"Implantable Microdevice In Primary Brain Tumors","status":"RECRUITING","sponsor":"Oliver Jonas","startDate":"2020-03-03","conditions":"Grade II Glioma, Grade III Glioma, Grade IV Glioma","enrollment":12},{"nctId":"NCT03632135","phase":"PHASE3","title":"Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Cordgenics, LLC","startDate":"2018-05-20","conditions":"Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT04421378","phase":"PHASE1, PHASE2","title":"A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-06-08","conditions":"Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT06419946","phase":"PHASE3","title":"Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2024-12-01","conditions":"Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma","enrollment":200},{"nctId":"NCT04530006","phase":"NA","title":"Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma","status":"UNKNOWN","sponsor":"CancerCare Manitoba","startDate":"2020-12-02","conditions":"Glioblastoma Multiforme","enrollment":20},{"nctId":"NCT03425292","phase":"PHASE1","title":"A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2018-03-01","conditions":"Newly Diagnosed High Grade Glioma","enrollment":49},{"nctId":"NCT03463265","phase":"PHASE2","title":"Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Aadi Bioscience, Inc.","startDate":"2018-08-01","conditions":"High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma","enrollment":62},{"nctId":"NCT03951142","phase":"PHASE2","title":"Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study","status":"UNKNOWN","sponsor":"Kyrre Eeg Emblem","startDate":"2019-10-01","conditions":"Glioblastoma, Brain Metastases","enrollment":165},{"nctId":"NCT00100802","phase":"PHASE2","title":"Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-03-21","conditions":"Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma","enrollment":118},{"nctId":"NCT02843230","phase":"","title":"Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-08-01","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT02796261","phase":"PHASE3","title":"Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients","status":"UNKNOWN","sponsor":"Orbus Therapeutics, Inc.","startDate":"2016-07","conditions":"Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma","enrollment":343},{"nctId":"NCT02678975","phase":"PHASE2, PHASE3","title":"Disulfiram in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2017-01","conditions":"Glioma, Glioblastoma","enrollment":88},{"nctId":"NCT02343406","phase":"PHASE2","title":"Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-02-17","conditions":"Glioblastoma","enrollment":266},{"nctId":"NCT02414165","phase":"PHASE2, PHASE3","title":"The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma","status":"TERMINATED","sponsor":"Tocagen Inc.","startDate":"2015-11-30","conditions":"Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":403},{"nctId":"NCT00004259","phase":"PHASE3","title":"Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-06","conditions":"Brain and Central Nervous System Tumors","enrollment":230},{"nctId":"NCT00527657","phase":"PHASE1","title":"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-09","conditions":"Brain Neoplasms, Melanoma","enrollment":17},{"nctId":"NCT01860638","phase":"PHASE2","title":"A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-19","conditions":"Glioblastoma","enrollment":296},{"nctId":"NCT01149109","phase":"PHASE3","title":"Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients","status":"COMPLETED","sponsor":"University Hospital, Bonn","startDate":"2010-10","conditions":"Glioblastoma","enrollment":141},{"nctId":"NCT00335075","phase":"PHASE3","title":"Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03-02","conditions":"Glioblastoma, Astrocytoma","enrollment":151},{"nctId":"NCT00761280","phase":"PHASE3","title":"Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma","status":"TERMINATED","sponsor":"Isarna Therapeutics GmbH","startDate":"2008-12","conditions":"Anaplastic Astrocytoma, Glioblastoma","enrollment":27},{"nctId":"NCT00006024","phase":"PHASE1","title":"Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-11","conditions":"Brain Tumor, Central Nervous System Tumor","enrollment":32},{"nctId":"NCT00052455","phase":"PHASE3","title":"Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2002-10","conditions":"Brain and Central Nervous System Tumors","enrollment":500},{"nctId":"NCT00431561","phase":"PHASE2","title":"Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma","status":"COMPLETED","sponsor":"Isarna Therapeutics GmbH","startDate":"2003-04","conditions":"Glioblastoma, Anaplastic Astrocytoma","enrollment":141},{"nctId":"NCT00072345","phase":"PHASE2","title":"Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-07","conditions":"Intraocular Melanoma, Melanoma (Skin)","enrollment":""},{"nctId":"NCT00504660","phase":"PHASE2","title":"6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-09","conditions":"Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer","enrollment":75},{"nctId":"NCT00717210","phase":"PHASE3","title":"Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide","status":"COMPLETED","sponsor":"Neuro-Oncology Working Group of the German Cancer Society","startDate":"1999-06","conditions":"Anaplastic Astrocytoma, Oligodendroglioma, Oligoastrocytoma","enrollment":318}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":293,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Temodal, Temomedac, CeCeNu"],"phase":"phase_3","status":"active","brandName":"Temozolomide and lomustine","genericName":"Temozolomide and lomustine","companyName":"University Hospital, Bonn","companyId":"university-hospital-bonn","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temozolomide and lomustine (also known as semustine) are small molecule DNA inhibitors used to treat various types of brain and central nervous system tumors, including glioblastoma, astrocytoma, and melanoma. They are classified as inhibitors and have been studied in clinical trials for their efficacy and safety in treating these conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}